Differential Antifungal Activity of Isomeric Forms of Nystatin
Open Access
- 1 October 2001
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (10), 2781-2786
- https://doi.org/10.1128/aac.45.10.2781-2786.2001
Abstract
When nystatin is placed in RPMI and other biological fluids, there is loss of pure nystatin, with the development of two distinguishable chromatographic peaks, 1 and 2. Peak 1 appears identical to commercially prepared nystatin. By nuclear magnetic resonance (NMR) and mass spectral analysis, peak 2 appears to be an isomer of peak 1. The isomers are quantitatively and fully interconvertible. Formation of peak 2 is accelerated at a pH of >7.0 and ultimately reaches a near 55:45 (peak 1/peak 2 ratio) mixture. We sought to determine the relative activities of peaks 1 and 2 against Candida spp. Peak 2 consistently showed higher MICs when it was the predominant form during the experiment. Time-kill analyses showed that peak 2 required ≥8× the concentration of peak 1 to produce a modest and delayed killing effect, which was never of the same magnitude as that produced by peak 1. In both types of assays, the activity of peak 2 corresponded with intra-assay formation of peak 1. Both MIC measurements and time-kill analysis suggest that peak 2 has considerably less activity, if any at all, against Candida spp. Peak 2 may serve as a reservoir for peak 1.Keywords
This publication has 23 references indexed in Scilit:
- Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2000
- Multiple resistance mechanisms to azole antifungals in yeast clinical isolatesDrug Resistance Updates, 1998
- Risk factors for systemic fungal infections in liver transplant recipientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- Changes in the spectrum of fungal isolates: results from clinical specimens gathered in 1987/88 compared with those in 1991/92 in the University Hospital Gottingen, GermanyMycoses, 1993
- Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised hostJournal of Antimicrobial Chemotherapy, 1991
- Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infectionsAntimicrobial Agents and Chemotherapy, 1987
- Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasisAntimicrobial Agents and Chemotherapy, 1987
- The effect of pH and of temperature on the stability and bioactivity of nystatin and amphotericin BJournal of Pharmacy and Pharmacology, 1973
- The Polyene Antifungal AntibioticsPublished by Springer Nature ,1963
- Polyene AntibioticsScience, 1955